{"id":"camrelizumab-plus-apatinib","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hypertension"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Camrelizumab works by binding to PD-1 and blocking its interaction with PD-L1, thereby enhancing T-cell activation and proliferation. Apatinib, on the other hand, inhibits VEGFR-2, which is involved in angiogenesis and tumor growth.","oneSentence":"Camrelizumab is a PD-1 inhibitor, and Apatinib is a VEGFR-2 tyrosine kinase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:24.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastric cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT03083041","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-03-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":210},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":"Advanced Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT03092895","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-04-24","conditions":"Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma","enrollment":157},{"nctId":"NCT06693128","phase":"PHASE2","title":"Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-21","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":80},{"nctId":"NCT04208347","phase":"PHASE2, PHASE3","title":"Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2019-12-18","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":580},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT04342910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-21","conditions":"Gastric Cancer","enrollment":550},{"nctId":"NCT07351513","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult","enrollment":86},{"nctId":"NCT07334483","phase":"PHASE2","title":"A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC","status":"RECRUITING","sponsor":"GrandPharma (China) Co., Ltd.","startDate":"2025-08-22","conditions":"HCC","enrollment":120},{"nctId":"NCT07324473","phase":"PHASE2","title":"Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation","enrollment":65},{"nctId":"NCT04639180","phase":"PHASE3","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":687},{"nctId":"NCT07309419","phase":"PHASE2, PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":"Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT07267806","phase":"PHASE3","title":"Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"Linhui Peng","startDate":"2025-10-31","conditions":"Hepato Cellular Carcinoma (HCC), Chemotherapy Effect","enrollment":326},{"nctId":"NCT05320692","phase":"PHASE3","title":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-09","conditions":"Hepatocellular Carcinoma","enrollment":423},{"nctId":"NCT06172205","phase":"PHASE3","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect","enrollment":262},{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":"HCC - Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT05367687","phase":"PHASE2","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-09-01","conditions":"Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","enrollment":251},{"nctId":"NCT06349317","phase":"PHASE2","title":"Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT","status":"RECRUITING","sponsor":"Yongyi Zeng","startDate":"2024-04-22","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT03813784","phase":"PHASE3","title":"A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-07","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":885},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07156617","phase":"","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":2000},{"nctId":"NCT07154082","phase":"PHASE2","title":"Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Wei Zhang","startDate":"2025-12-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT07147101","phase":"","title":"Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":150},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT07105748","phase":"PHASE2","title":"HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":"Mixed Hepatocellular-cholangiocarcinoma","enrollment":45},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT04560127","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09-23","conditions":"Radioactive Iodine-refractory Differentiated Thyroid Cancer","enrollment":20},{"nctId":"NCT03777124","phase":"PHASE2","title":"Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-11","conditions":"NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody","enrollment":25},{"nctId":"NCT07026149","phase":"PHASE2","title":"Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-08","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":30},{"nctId":"NCT04625803","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-01-04","conditions":"Colon Cancer, Neoadjuvant Therapy","enrollment":64},{"nctId":"NCT06831175","phase":"PHASE2","title":"Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-03-15","conditions":"Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer","enrollment":28},{"nctId":"NCT06280105","phase":"PHASE2","title":"A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib","status":"RECRUITING","sponsor":"Meng Chao Hepatobiliary Hospital of Fujian Medical University","startDate":"2024-03-31","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":"Breast Cancer Stage IV","enrollment":246},{"nctId":"NCT05409482","phase":"","title":"A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Meng Chao Hepatobiliary Hospital of Fujian Medical University","startDate":"2022-08-20","conditions":"Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT04521153","phase":"PHASE2, PHASE3","title":"Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-03-25","conditions":"Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy","enrollment":294},{"nctId":"NCT04195828","phase":"PHASE2","title":"Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2020-06-18","conditions":"Advanced Gastric Cancer","enrollment":106},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT05512481","phase":"PHASE2","title":"Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-09-13","conditions":"Melanoma, Acral Melanoma, Temozolomide","enrollment":60},{"nctId":"NCT06796803","phase":"PHASE2, PHASE3","title":"Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-02-20","conditions":"Potentially Resectable Hepatocellular Carcinoma","enrollment":398},{"nctId":"NCT06759090","phase":"PHASE2","title":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-15","conditions":"Metastatic Pancreatic Carcinoma","enrollment":43},{"nctId":"NCT05613478","phase":"PHASE3","title":"Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-01-31","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":130},{"nctId":"NCT06745193","phase":"PHASE2","title":"A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-02-01","conditions":"Advanced Esophageal Carcinoma","enrollment":63},{"nctId":"NCT06739317","phase":"PHASE2, PHASE3","title":"SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC)","enrollment":398},{"nctId":"NCT03878472","phase":"PHASE2","title":"Neoadjuvant Immunotherapy for Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2019-04-01","conditions":"Gastric Cancer","enrollment":25},{"nctId":"NCT04701060","phase":"PHASE2","title":"Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-01-26","conditions":"Resectable Hepatocellular Carcinoma","enrollment":31},{"nctId":"NCT06644430","phase":"","title":"Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-04","conditions":"Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis","enrollment":470},{"nctId":"NCT06708650","phase":"NA","title":"Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guiping People's Hospital","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors","enrollment":50},{"nctId":"NCT05738434","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-03-02","conditions":"Esophageal Cancer by AJCC V8 Stage","enrollment":188},{"nctId":"NCT06694324","phase":"PHASE2","title":"First-line Treatment of Advanced/unresectable DDLPS","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)","enrollment":49},{"nctId":"NCT06632522","phase":"PHASE2","title":"Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-10-20","conditions":"Liver Cancer","enrollment":46},{"nctId":"NCT06632106","phase":"","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-08-16","conditions":"Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors","enrollment":97},{"nctId":"NCT06607107","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-02-17","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":29},{"nctId":"NCT06546280","phase":"PHASE2","title":"A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2024-08-26","conditions":"Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT03417895","phase":"PHASE2","title":"SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-20","conditions":"Small-cell Lung Cancer","enrollment":59},{"nctId":"NCT05412589","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-06-10","conditions":"Stage III Hepatocellular Cancer (CNLC Staging)","enrollment":35},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT04715633","phase":"PHASE2","title":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":53},{"nctId":"NCT06485466","phase":"PHASE3","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guohui Xu","startDate":"2024-07-01","conditions":"Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab","enrollment":101},{"nctId":"NCT06485271","phase":"","title":"A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhi People's Hospital Affiliated to Changzhi Medical College","startDate":"2023-11-01","conditions":"Gastric Cancer, RWS, PD-1 Immunotherapy","enrollment":504},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06360042","phase":"PHASE2","title":"Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-01-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":111},{"nctId":"NCT06376773","phase":"","title":"Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2022-06-01","conditions":"Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis","enrollment":234},{"nctId":"NCT06363825","phase":"PHASE2","title":"A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2024-04-12","conditions":"Advanced Hepatocellular Carcinoma","enrollment":57},{"nctId":"NCT03711279","phase":"PHASE2","title":"A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-11-22","conditions":"Sarcoma","enrollment":99},{"nctId":"NCT05924997","phase":"PHASE1, PHASE2","title":"Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":52},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT03764293","phase":"PHASE3","title":"A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-06-10","conditions":"Locally Advanced or Metastatic and Unresectable HCC","enrollment":543},{"nctId":"NCT04720131","phase":"PHASE2","title":"Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-01","conditions":"Biliary Tract Cancer, Anti-PD-1 Therapy, Targeted Molecular Therapy","enrollment":28},{"nctId":"NCT05062837","phase":"PHASE2, PHASE3","title":"Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-06-01","conditions":"Hepatocellular Carcinoma","enrollment":62},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT03472365","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-02","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":67},{"nctId":"NCT05839197","phase":"PHASE2","title":"A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC","status":"UNKNOWN","sponsor":"Wan-Guang Zhang","startDate":"2023-05-05","conditions":"Macrotrabecular Massive Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT04559607","phase":"NA","title":"TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2020-09-11","conditions":"Hepatocellular Carcinoma","enrollment":188},{"nctId":"NCT04379739","phase":"PHASE2","title":"Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-07-26","conditions":"Non Small Cell Lung Cancer","enrollment":89},{"nctId":"NCT05069857","phase":"PHASE2","title":"Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-09-01","conditions":"Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1","enrollment":46},{"nctId":"NCT04393506","phase":"PHASE1","title":"Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-04-23","conditions":"Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor","enrollment":21},{"nctId":"NCT06140732","phase":"PHASE2","title":"Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-10-30","conditions":"Chordoma, Chemotherapy Effect","enrollment":30},{"nctId":"NCT04074564","phase":"EARLY_PHASE1","title":"MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"HRYZ Biotech Co.","startDate":"2019-11-22","conditions":"Sarcoma","enrollment":60},{"nctId":"NCT04191889","phase":"PHASE2","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-13","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":47},{"nctId":"NCT05789043","phase":"PHASE3","title":"Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-03-21","conditions":"Acral Melanoma","enrollment":140},{"nctId":"NCT04135690","phase":"PHASE2","title":"HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-20","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05099848","phase":"PHASE2","title":"A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-03-17","conditions":"Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT04930315","phase":"PHASE2","title":"SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2021-09-15","conditions":"Hepatocellular Carcinoma","enrollment":78},{"nctId":"NCT05447702","phase":"PHASE2","title":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2022-11-01","conditions":"Triple Negative Breast Cancer","enrollment":35},{"nctId":"NCT05854849","phase":"PHASE3","title":"Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-01","conditions":"Nasopharyngeal Carcinoma","enrollment":244},{"nctId":"NCT04586088","phase":"PHASE2","title":"Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-05-05","conditions":"Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma","enrollment":58},{"nctId":"NCT04335006","phase":"PHASE3","title":"A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-14","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":80},{"nctId":"NCT04609176","phase":"PHASE2","title":"Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2020-11-18","conditions":"Gastric Cancer","enrollment":64},{"nctId":"NCT04454905","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-08-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT04303741","phase":"PHASE2","title":"A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-03-25","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT05556200","phase":"PHASE2","title":"A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-12-01","conditions":"Breast Cancer, Triple-Negative Breast Cancer","enrollment":58},{"nctId":"NCT03816553","phase":"PHASE2","title":"SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-01-19","conditions":"Recurrent Cervical Carcinoma, Metastatic Cervical Cancer","enrollment":45},{"nctId":"NCT05760430","phase":"PHASE2","title":"The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-14","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05742750","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer","enrollment":48},{"nctId":"NCT04803539","phase":"PHASE2, PHASE3","title":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-01","conditions":"Breast Cancer","enrollment":260},{"nctId":"NCT05549466","phase":"PHASE2","title":"Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-08","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Camrelizumab plus Apatinib","genericName":"Camrelizumab plus Apatinib","companyName":"Wan-Guang Zhang","companyId":"wan-guang-zhang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor, and Apatinib is a VEGFR-2 tyrosine kinase inhibitor. Used for Advanced gastric cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}